EGFR and non-small cell lung carcinoma: Moreover, a phase II trial, which is currently recruiting patients with NSCLC bearing EGFR/HER2 mutations, has reported some early signs of clinical activity for the HER2 exon 20 p.A775_G776insYVMA mutation84.